The United States Food and Drug Administration approved Bayer’s Lampit (nifurtimox) for use in pediatric patients for the treatment of Chagas disease caused by Trypanosoma cruzi.

Medicines Development for Global Health and the World Health Organization Special Programme for Research and Training in Tropical Diseases announced that the U.S. FDA approved moxidectin 8 mg oral for the treatment of river blindness (onchocerciasis) in patients aged 12 years and older.

Merck announced today a $300,000 cash donation to support non-governmental organization partners working to eliminate river blindness (onchocerciasis) and lymphatic filariasis (LF) in Africa.